INSYS Therapeutics inks deal with Lunatus to commercialize SUBSYS in the Middle East

|By:, SA News Editor

INSYS Therapeutics (NASDAQ:INSY) has signed a definitive license agreement with Lunatus for commercialization of SUBSYS (fentanyl sublingual spray) in eight countries in the Middle East, which comprises Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia and the United Arab Emirates (the territory).

Under the terms of this 10-year agreement, INSYS will supply SUBSYS to Lunatus, and Lunatus will obtain the regulatory approvals and commercialize SUBSYS in the territory.

Financial terms are not disclosed.

Subscribe for full text news in your inbox